Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT02187848 trial: what clinicians have said so far
Evaluation of SAR408701 in Patients With Advanced Solid Tumors
- NCT02187848 ↗
- Terminated
- Sanofi
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT02187848 (tusamitamab ravtansine in advanced solid tumors) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT02187848 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- A First-in-Human Study for the Evaluation of the Safety, Pharmacokinetics and Antitumor Activity of SAR408701 in Patients With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Terminated
- Conditions
- Neoplasm Malignant
- Interventions
- SAR408701
- Arms
- SAR408701 Main Dose Escalation Cohort · Experimental
- SAR408701 Expansion Cohort colorectal cancer (CRC) · Experimental
- SAR408701 Expansion Cohort non-squamous NSCLC · Experimental
- SAR408701 Expansion Cohort gastric adenocarcinoma · Experimental
- SAR408701 Loading Dose Escalation cohorts (Escalation bis) · Experimental
- SAR408701 Expansion Cohort non-squamous NSCLC (Lung bis) · Experimental
- SAR408701 Expansion Cohort colorectal cancer (CRC-L) · Experimental
- SAR408701 Expansion Cohort small cell lung cancer (SCLC) · Experimental
- SAR408701 Dose Escalation every 3 weeks cohort · Experimental
- Enrollment
- 254
- Primary outcomes
- Number of dose limiting adverse events (every 2 week cycle)
- Assessment of overall response rate using standard imaging and RECIST 1.1 criteria
- Number of dose limiting adverse events (every 3 week cycle)
- Sponsor
- Sanofi
- Start
- Jul 23, 2014
- Primary completion
- Nov 10, 2020
- Results posted
- No
- Registry record
- NCT02187848 · updated Feb 10, 2025
Publications
linked from the registry- Gazzah A, Bedard PL, Hierro C, Kang YK, Abdul Razak A, Ryu MH, Demers B, Fagniez N, Henry C, Hospitel M, Soria JC, Tabernero J. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022 Apr;33(4):416-425. doi: 10.1016/j.annonc.2021.12.012. Epub 2022 Jan 10. PubMed 35026412
- Tabernero J, Bedard PL, Bang YJ, Vieito M, Ryu MH, Fagniez N, Chadjaa M, Soufflet C, Masson N, Gazzah A. Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens. Cancer Res Commun. 2023 Aug 28;3(8):1662-1671. doi: 10.1158/2767-9764.CRC-23-0284. eCollection 2023 Aug. PubMed 37645622
- Gazzah A, Ternes N, Lee JS, Wang E, Carene D, Wang H, Masson N, Boitier E, Lartigau A, Mace N, Chadjaa M, Dib C, Nunes M, Muzard G, Longuemaux-Valence S, Bauchet AL. Biomarker analysis from a Phase 1/1b study of tusamitamab ravtansine in patients with advanced non-small cell lung cancer. Transl Oncol. 2026 Jan;63:102615. doi: 10.1016/j.tranon.2025.102615. Epub 2025 Dec 3. PubMed 41337813